HHS’ Health Resources and Services Administration unveiled details of a revised 340B rebate pilot that would allow some drug manufacturers to deny rebates for a small subset of products. Pharma groups backed the change, positioning it as a more workable version of the agency’s pilot design. The updated framework could affect hospital purchasing economics and contract negotiations, especially for therapies carved into rebate-eligible versus rebate-exempt categories. For biotech manufacturers, it introduces a new lever in how drug pricing, rebate exposure, and payer mix may play out across the 340B hospital channel.